The disease caused by SARS-CoV-2 is still considered a global pandemic. Transdermal patches (TP) with immunoregulators such as
estrogen and
progesterone compounds could be a feasible option to treat
COVID-19 because of their accessibility and relative safety. The objective of the current study was to evaluate the additional treatment with
norelgestromin and ethinylestradiol in TP on the clinical and biochemical evolution of
COVID-19 patients. The present is a clinical-trial pilot study that included subjects diagnosed with
COVID-19, randomized into two groups; the experimental Evra® TP (
norelgestromin 6 mg and ethinylestradiol 0.60 mg) was administered such that it was applied on arrival and replaced at day 8 and day 15. The control continued with the conventional
COVID-19 treatment protocol. A blood sample was taken each week in order to evaluate relevant biochemical parameters, clinical signs, and evolution. In total, 44 subjects participated in this study, 30 in the experimental group and 14 in the control group. Both groups were homogeneous in terms of age and comorbidities. The experimental group had a significantly lower
hospital stay (p = 0.01), high flow supplemental
oxygen (p = 0.001),
mechanical ventilation (p = 0.003), and intubation (p = 0.01), and the oxygen saturation significantly increased (p = 0.01) in comparison with control group when patients were exposed to room air. A decrease in
ferritin (p < 0.05) was observed, with no significant increase in ESR (p > 0.05),
D dimer (p > 0.05) and platelets (p > 0.05) in an auto-controlled analysis in the experimental group.
Norelgestromin and ethinylestradiol TP could be a safe and effective treatment for moderate and severe
COVID-19 patients.